Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical Ingredient

Currently, treatment of Chagas disease is restricted to the use of benznidazole and nifurtimox; however, nifurtimox was temporarily suspended in some countries. Based on the limitations in pharmacological treatments, it is essential to guarantee the quality of benznidazole. Therefore, this work aimed to identify the degradation products of benznidazole and to validate a stability indicating method. The stability test was performed through a forced degradation study, exposing benznidazole under a range of conditions. Benznidazole proved to be unstable under acidic and alkaline conditions, and three products were identified by liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer (UPLC-QTOF-MS). Furthermore, a stability indicating method by high performance liquid chromatography with a diode array detector (HPLC-DAD) for benznidazole was developed and validated according to ICH (International Conference on Harmonisation) and ANVISA (Agência Nacional de Vigilância Sanitária) guidelines. The method was linear (180-420 µg mL-1 range), selective in the presence of degradation products, precise (relative standard deviation (RSD) < 0.6%), accurate (recovery > 99.2%), robust, and free of matrix effects. The method was successfully able to quantify the benznidazole in pharmaceutical formulations.

Saved in:
Bibliographic Details
Main Authors: Kawaguchi,Wilton H., Fachi,Mariana M., Cerqueira,Leticia B., Campos,Michel L., Gonçalves,Alan G., Trindade,Angela C. L. B., Reason,Iara J. M., Pontarolo,Roberto
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Química 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532020000601194
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0103-50532020000601194
record_format ojs
spelling oai:scielo:S0103-505320200006011942020-06-04Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical IngredientKawaguchi,Wilton H.Fachi,Mariana M.Cerqueira,Leticia B.Campos,Michel L.Gonçalves,Alan G.Trindade,Angela C. L. B.Reason,Iara J. M.Pontarolo,Roberto benznidazole Chagas disease degradation products stability indicating method Currently, treatment of Chagas disease is restricted to the use of benznidazole and nifurtimox; however, nifurtimox was temporarily suspended in some countries. Based on the limitations in pharmacological treatments, it is essential to guarantee the quality of benznidazole. Therefore, this work aimed to identify the degradation products of benznidazole and to validate a stability indicating method. The stability test was performed through a forced degradation study, exposing benznidazole under a range of conditions. Benznidazole proved to be unstable under acidic and alkaline conditions, and three products were identified by liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer (UPLC-QTOF-MS). Furthermore, a stability indicating method by high performance liquid chromatography with a diode array detector (HPLC-DAD) for benznidazole was developed and validated according to ICH (International Conference on Harmonisation) and ANVISA (Agência Nacional de Vigilância Sanitária) guidelines. The method was linear (180-420 µg mL-1 range), selective in the presence of degradation products, precise (relative standard deviation (RSD) < 0.6%), accurate (recovery > 99.2%), robust, and free of matrix effects. The method was successfully able to quantify the benznidazole in pharmaceutical formulations.info:eu-repo/semantics/openAccessSociedade Brasileira de QuímicaJournal of the Brazilian Chemical Society v.31 n.6 20202020-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532020000601194en10.21577/0103-5053.20200005
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Kawaguchi,Wilton H.
Fachi,Mariana M.
Cerqueira,Leticia B.
Campos,Michel L.
Gonçalves,Alan G.
Trindade,Angela C. L. B.
Reason,Iara J. M.
Pontarolo,Roberto
spellingShingle Kawaguchi,Wilton H.
Fachi,Mariana M.
Cerqueira,Leticia B.
Campos,Michel L.
Gonçalves,Alan G.
Trindade,Angela C. L. B.
Reason,Iara J. M.
Pontarolo,Roberto
Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical Ingredient
author_facet Kawaguchi,Wilton H.
Fachi,Mariana M.
Cerqueira,Leticia B.
Campos,Michel L.
Gonçalves,Alan G.
Trindade,Angela C. L. B.
Reason,Iara J. M.
Pontarolo,Roberto
author_sort Kawaguchi,Wilton H.
title Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical Ingredient
title_short Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical Ingredient
title_full Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical Ingredient
title_fullStr Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical Ingredient
title_full_unstemmed Stability Indicating Method for Determination of Benznidazole and Its Degradation Products in Active Pharmaceutical Ingredient
title_sort stability indicating method for determination of benznidazole and its degradation products in active pharmaceutical ingredient
description Currently, treatment of Chagas disease is restricted to the use of benznidazole and nifurtimox; however, nifurtimox was temporarily suspended in some countries. Based on the limitations in pharmacological treatments, it is essential to guarantee the quality of benznidazole. Therefore, this work aimed to identify the degradation products of benznidazole and to validate a stability indicating method. The stability test was performed through a forced degradation study, exposing benznidazole under a range of conditions. Benznidazole proved to be unstable under acidic and alkaline conditions, and three products were identified by liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer (UPLC-QTOF-MS). Furthermore, a stability indicating method by high performance liquid chromatography with a diode array detector (HPLC-DAD) for benznidazole was developed and validated according to ICH (International Conference on Harmonisation) and ANVISA (Agência Nacional de Vigilância Sanitária) guidelines. The method was linear (180-420 µg mL-1 range), selective in the presence of degradation products, precise (relative standard deviation (RSD) < 0.6%), accurate (recovery > 99.2%), robust, and free of matrix effects. The method was successfully able to quantify the benznidazole in pharmaceutical formulations.
publisher Sociedade Brasileira de Química
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532020000601194
work_keys_str_mv AT kawaguchiwiltonh stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
AT fachimarianam stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
AT cerqueiraleticiab stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
AT camposmichell stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
AT goncalvesalang stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
AT trindadeangelaclb stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
AT reasoniarajm stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
AT pontaroloroberto stabilityindicatingmethodfordeterminationofbenznidazoleanditsdegradationproductsinactivepharmaceuticalingredient
_version_ 1756403806798610432